Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Capricor Therapeutics, Inc. CAPR
$4.01
-$0.1 (-2.43%)
На 18:01, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
107295441.00000000
-
week52high
6.58
-
week52low
2.81
-
Revenue
2548918
-
P/E TTM
-3
-
Beta
4.02041500
-
EPS
-1.19000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 31 янв 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 11 окт 2021 г. |
| Roth Capital | Buy | 25 ноя 2020 г. | |
| Maxim Group | Buy | 25 ноя 2020 г. | |
| H.C. Wainwright | Buy | Buy | 25 ноя 2020 г. |
| Ladenburg Thalmann | Buy | 26 окт 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Bergmann Anthony | A | 85000 | 85000 | 03 янв 2023 г. |
| Krasney Karen | A | 11878 | 11878 | 03 янв 2023 г. |
| Krasney Karen | A | 80000 | 80000 | 03 янв 2023 г. |
| Marban Linda | A | 135000 | 135000 | 03 янв 2023 г. |
| Litvack Frank | A | 185000 | 185000 | 03 янв 2023 г. |
| COLLIER EARL M JR | A | 19000 | 19000 | 03 янв 2023 г. |
| COLLIER EARL M JR | A | 11870 | 11870 | 03 янв 2023 г. |
| COLLIER EARL M JR | A | 37770 | 37770 | 03 янв 2023 г. |
| DUNBAR GEORGE W JR | A | 19000 | 19000 | 03 янв 2023 г. |
| DUNBAR GEORGE W JR | A | 8310 | 8310 | 03 янв 2023 г. |
Новостная лента
Capricor Therapeutics, Inc. (CAPR) Q1 2023 Earnings Call Transcript
Seeking Alpha
11 мая 2023 г. в 17:55
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants AJ Bergmann - CFO Linda Marban - CEO Conference Call Participants Aydin Huseynov - Ladenburg Operator Good afternoon, ladies and gentlemen, this is the conference operator. Welcome to Capricor First Quarter 2023 Financial Results and Corporate Update Call.
Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15
GlobeNewsWire
08 мар 2023 г. в 09:00
-Company to Host Conference Call, March 15, 2023, at 4:30 p.m. ET- -Company to Host Conference Call, March 15, 2023, at 4:30 p.m. ET-
Capricor (CAPR) Upgraded to Buy: What Does It Mean for the Stock?
Zacks Investment Research
11 янв 2023 г. в 13:33
Capricor (CAPR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Capricor Therapeutics, Inc. (CAPR) Q3 2022 Earnings Call Transcript
Seeking Alpha
10 ноя 2022 г. в 22:21
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q3 2022 Results Conference Call November 10, 2022 4:30 PM ET Company Participants AJ Bergmann - CFO Linda Marbán - CEO Conference Call Participants Alan Leong - BioWatch News Aydin Huseynov - Ladenburg Brian Corday - BullBear Partners Operator Good day, ladies and gentlemen, and welcome to the Capricor Therapeutics Incorporated Third Quarter 2022 Earnings Call. Today's conference is being recorded.
Capricor Therapeutics (CAPR) Reports Q3 Loss, Tops Revenue Estimates
Zacks Investment Research
10 ноя 2022 г. в 18:48
Capricor (CAPR) delivered earnings and revenue surprises of 7.14% and 279.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?